News on Mendelian diseases, hereditary cancer, variant classification, cystic fibrosis testing and more.
The new assay is part of the company's prenatal and women's health offerings, but it is also developing a preeclampsia test and technology for gastrointestinal testing.
Orto+ will be market and distribute Todos' TM-B2 test for breast cancer screening in Romania and Austria. The test is CE marked.
A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.